Vertex Pharmaceuticals Inc (VRTX) fundamentals from SEC filings — revenue $12.0B, net margin 32.9%, diluted EPS $15.32 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Net income | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| Net margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% |
| Diluted EPS | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| Free cash flow | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home